Leerink Partnrs Issues Positive Estimate for HIMS Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Equities researchers at Leerink Partnrs boosted their Q1 2025 earnings per share (EPS) estimates for shares of Hims & Hers Health in a report released on Tuesday, February 25th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings of $0.11 per share for the quarter, up from their previous forecast of $0.10. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.29 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s Q2 2025 earnings at $0.13 EPS, Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.17 EPS, FY2025 earnings at $0.56 EPS, FY2026 earnings at $0.75 EPS and FY2027 earnings at $1.15 EPS.

Other equities research analysts also recently issued reports about the stock. Truist Financial lifted their price target on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Piper Sandler increased their price target on Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday. TD Cowen reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Finally, Morgan Stanley downgraded Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $34.47.

Hims & Hers Health Trading Up 5.0 %

Hims & Hers Health stock opened at $41.87 on Thursday. The stock has a market cap of $9.15 billion, a PE ratio of 95.15 and a beta of 1.35. The stock has a 50-day moving average price of $35.89 and a 200 day moving average price of $26.36. Hims & Hers Health has a 52 week low of $11.20 and a 52 week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently modified their holdings of HIMS. Crewe Advisors LLC acquired a new position in Hims & Hers Health during the 4th quarter worth approximately $28,000. Raleigh Capital Management Inc. lifted its position in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. boosted its stake in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC grew its holdings in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new stake in Hims & Hers Health during the 4th quarter valued at $38,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 268,932 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the transaction, the insider now directly owns 169,803 shares of the company’s stock, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $33.56, for a total value of $68,932.24. Following the transaction, the insider now owns 184,947 shares in the company, valued at approximately $6,206,821.32. This represents a 1.10 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,097,578 shares of company stock worth $38,080,320. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.